Cue Health price target lowered to $0.75 from $1.50 at TD Cowen

TD Cowen lowered the firm’s price target on Cue Health to $0.75 from $1.50 and keeps an Outperform rating on the shares. The firm said following the FDA declining to issue an EUA for Flu COVID multiplex test there is an increased importance on potential regulatory approval of the RSV test and the Flu test under FDA review and new tests are needed to reaccelerate growth and improve margins